Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease.

[1]  T. Hastings.  Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.

[2]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[3]  J. Haycock,et al.  Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain , 1994, Brain Research.

[4]  M. Zigmond,et al.  Identification of Catechol‐Protein Conjugates in Neostriatal Slices Incubated with [3H]Dopamine: Impact of Ascorbic Acid and Glutathione , 1994, Journal of neurochemistry.

[5]  J. Townsend,et al.  Pre- and Postsynaptic Neurotoxic Effects of Dopamine Demonstrated by Intrastriatal Injection , 1993, Experimental Neurology.

[6]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[7]  Y. Agid,et al.  Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? , 1992, Journal of neurochemistry.

[8]  E. Abercrombie,et al.  Neurochemical Responses to 6‐Hydroxydopamine and L‐Dopa Therapy: Implications for Parkinson's Disease a , 1992, Annals of the New York Academy of Sciences.

[9]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[10]  A. Carlsson,et al.  Vitamin C Deficiency Facilitates 5‐S‐Cysteinyldopamine Formation in Guinea Pig Striatum , 1991, Journal of neurochemistry.

[11]  E. Rosengren,et al.  5-S-cysteinyldopac in human urine. , 1990, Acta dermato-venereologica.

[12]  F. Hefti,et al.  Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.

[13]  A. Carlsson,et al.  In Vivo Autoxidation of Dopamine in Guinea Pig Striatum Increases with Age , 1990, Journal of neurochemistry.

[14]  A. Carlsson,et al.  An Improved HPLC‐Electrochemical Detection Method for Measuring Brain Levels of 5‐S‐Cysteinyldopamine, 5‐S‐Cysteinyl‐3,4‐Dihydroxyphenylalanine, and 5‐S‐Cysteinyl‐3,4‐Dihydroxyphenylacetic Acid , 1990, Journal of neurochemistry.

[15]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[16]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[17]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[18]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[19]  S. Ito,et al.  Covalent binding of catechols to proteins through the sulphydryl group. , 1988, Biochemical pharmacology.

[20]  M. Shipley,et al.  Serotonergic afferents to the rat olfactory bulb: I. Origins and laminar specificity of serotonergic inputs in the adult rat , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[21]  M. Murray,et al.  Normal development and effects of early deafferentation on choline acetyltransferase, substance P and serotonin-like immunoreactivity in the interpeduncular nucleus , 1987, Brain Research.

[22]  T. Kato,et al.  Tyrosinase-catalyzed binding of 3,4-dihydroxyphenylalanine with proteins through the sulfhydryl group. , 1986, Biochimica et biophysica acta.

[23]  J. Weinberger,et al.  Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-para-tyrosine. , 1985, Stroke.

[24]  S. Kish,et al.  Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.

[25]  C. J. Schmidt,et al.  Role of dopamine in the neurotoxic effects of methamphetamine. , 1985, The Journal of pharmacology and experimental therapeutics.

[26]  M. Zigmond,et al.  Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. , 1984, Archives of neurology.

[27]  D. Godin,et al.  Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.

[28]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[29]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[30]  J. Daly,et al.  Oxygen-dependent reaction of 6-hydroxydopamine, 5,6-dihydroxytryptamine, and related compounds with proteins in vitro: a model for cytotoxicity. , 1976, Molecular pharmacology.

[31]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[32]  M. Scheulen,et al.  Irreversible binding of DOPA and dopamine metabolites to protein by rat liver microsomes. , 1975, Biochemical and biophysical research communications.

[33]  M. Maguire,et al.  The Reaction of [3H]Norepinephrine with Particulate Fractions of Cells Responsive to Catecholamines , 1974 .

[34]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[35]  H. Thoenen,et al.  Model experiments on the molecular mechanism of action of 6-hydroxydopamine. , 1971, Molecular pharmacology.

[36]  W. Becker.  [The effect of the exocrine secretion of the pancreas on blood sugar regulation. I. Research after ligation of the pancreatic duct, after subtotal pancreatic resection, and after extensive destruction of the pancreas]. , 1958, Acta neurovegetativa.

[37]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[38]  Y Agid,et al.  Are dopaminergic neurons selectively vulnerable to Parkinson's disease? , 1993, Advances in neurology.

[39]  A. Carlsson,et al.  The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra , 1989, Journal of neural transmission. Parkinson's disease and dementia section.

[40]  G. Cohen.  The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. , 1983, Journal of neural transmission. Supplementum.

[41]  D. Tse,et al.  Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.